Antag Therapeutics has launched a Phase Ia trial for AT-7687, a GIPR antagonist aimed at treating obesity. The therapy targets a validated mechanism to enhance weight loss and improve tolerability of incretin-based treatments.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing